FY2025 · ended Dec 31, 2025 · Revenue $1.64B, +1.5% YoY · Filed Feb 26, 2026
Integra Lifesciences Holdings Corp (IART) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.6 billion and a net loss of $516.5 million. Free cash flow was -$31.1 million. As of Sep 30, 2026 it held $311.9 million in cash and investments and $873.2 million in total debt.
Revenue (TTM)
$1.66B
+0.8% vs year-ago TTM
Net income (TTM)
$13.01M
+102.6% vs year-ago TTM
Operating cash flow (TTM)
$140.40M
+57.2% vs year-ago TTM
Free cash flow (TTM)
$85.78M
+2000.4% vs year-ago TTM
EPS (TTM)
$0.17
+102.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
77.94M
+0.9% vs prior year
Net cash
$-561.25M
as of Sep 30, 2026
Operating margin
4.4%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- IART (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 917520
- Former names
- INTEGRA LIFESCIENCES CORP (until Mar 31, 1999)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | $1.5B | $1.6B | $1.5B |
| Operating income | -$493.4M | $28.4M | $111.5M | $238.9M | $197.2M |
| Net income | -$516.5M | -$6.9M | $67.7M | $180.6M | $169.1M |
| Diluted EPS | -$6.74 | -$0.09 | $0.84 | $2.16 | $1.98 |
| Operating cash flow | $50.4M | $129.4M | $140.0M | $264.5M | $312.4M |
| Free cash flow | -$31.1M | $25.0M | $73.1M | $222.1M | $264.4M |
| Total assets | $3.6B | $4.0B | $3.8B | $3.9B | $3.8B |
| Total liabilities | $2.6B | $2.5B | $2.2B | $2.1B | $2.1B |
| Stockholders' equity | $1.0B | $1.5B | $1.6B | $1.8B | $1.7B |
| Cash and investments | $263.7M | $273.6M | $309.1M | $456.7M | $513.4M |
| Total debt | $903.6M | $941.9M | $957.1M | $947.0M | $948.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 23, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 2, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
All 1000 Integra Lifesciences Holdings Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.